Geneos Wealth Management’s MGM Growth Properties LLC Class A common shares representing limited liability company interests MGP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-750
Closed -$29K 2869
2022
Q1
$29K Hold
750
﹤0.01% 1627
2021
Q4
$30K Sell
750
-3
-0.4% -$117 ﹤0.01% 1701
2021
Q3
$29K Hold
753
﹤0.01% 1746
2021
Q2
$27K Hold
753
﹤0.01% 1771
2021
Q1
$27K Sell
753
-3
-0.4% -$97 ﹤0.01% 1929
2020
Q4
$24K Buy
756
+6
+0.8% +$179 ﹤0.01% 1813
2020
Q3
$20K Hold
750
﹤0.01% 1668
2020
Q2
$20K Buy
+750
New +$19.3K ﹤0.01% 1628

Other funds holding MGP

Geneos Wealth Management's MGP Position: Q2 2022 in Review

Geneos Wealth Management sold out of MGM Growth Properties LLC Class A common shares representing limited liability company interests (MGP) in Q2 2022, closing a stake of 750 shares — an estimated $29K sold.

Geneos Wealth Management first reported a position in MGP in Q2 2020 and held it in 8 quarters. The position peaked at $30K in Q4 2021. 1 fund tracked by Wall St. Rank holds MGP as of Q2 2022.

  • Geneos Wealth Management reported no remaining MGM Growth Properties LLC Class A common shares representing limited liability company interests position as of Q2 2022 after selling out during the quarter.
  • Geneos Wealth Management sold 750 MGM Growth Properties LLC Class A common shares representing limited liability company interests shares in Q2 2022, an estimated $29K.
  • Geneos Wealth Management first reported a position in MGM Growth Properties LLC Class A common shares representing limited liability company interests in Q2 2020 and held it in 8 quarters.
  • Geneos Wealth Management's MGM Growth Properties LLC Class A common shares representing limited liability company interests position peaked at $30K in Q4 2021.
  • 1 fund tracked by Wall St. Rank held MGM Growth Properties LLC Class A common shares representing limited liability company interests as of Q2 2022.

Based on Geneos Wealth Management's 13F filing for Q2 2022, filed 22 Jul 2022.